Oxlumo® Lumasiran Injection for Primary Hyperoxaluria Type 1 Treatment

Name: Oxlumo® Lumasiran Injection for Primary Hyperoxaluria Type 1 Treatment
Brand: Oxlumo®
SKU: USAMP#91320513
Price: 80132 USD
Availability: InStock

USAMP#91320513SKU: 71336100201Oxlumo®

License Required

Product Spotlight

Oxlumo® Lumasiran is a cutting-edge HAO1-directed small interfering ribonucleic acid (siRNA) therapy designed specifically for the treatment of Primary Hyperoxaluria Type 1 (PH1), an ultra-rare and potentially life-threatening genetic disorder.
It effectively lowers urinary oxalate levels, addressing the root cause of PH1, and is suitable for use in both pediatric and adult patients.
Manufactured by Alnylam Pharmaceuticals Inc, this single-dose vial injection represents a significant advancement in the management of PH1.

Frequently Bought Together